Regulatory, Security Concerns Force Wuxi NextCODE To Cut China Ties
China Operations Face Potential Overhaul
Executive Summary
As China tightens its grip over clinical research using human genetic data in the country, and the US increases scrutiny over the use of personal data, multinational drug developers may face a difficult choice or even create separate entities to cater to local regulatory requirements. WuXi NextCODE provides one interesting case study.
You may also be interested in...
China Relaxes Restrictions Amid 'Zero' Severe Shanghai Cases
China is signalling its intention to gradually re-open its borders amid real-world data showing few mild-to-moderate cases progress to severe symptoms. Meanwhile, Pfizer's Paxlovid is seemingly struggling to gain traction amid use guideline changes.
CEO Podcast: Hengrui's US Subsidiary's CEO, CMO On Chinese Pharma Going Global
While many pharma firms in China choose to partner with US companies, Jiangsu Hengrui is relying on itself to go global. The Chinese pharma giant is betting on its newly established US subsidiary Luzsana in a major move to make its wide-ranging products more available, accessible and affordable to patients in the US and the rest of the world.
China's mRNA Shot Shows Benefits Over Older COVID Vaccines
Home-grown Chinese mRNA COVID-19 vaccines are more effective than domestic inactivated virus-based shots, new trial results show.